Dr. Craig Eagle is a valuable member of Wealth Management Consultants Outside Advisory Group. Dr. Eagle has extensive experience in drug development in the medical and biotechnology space. Some of the specific background within his extensive breath of knowledge and experience are:
Dr. Craig Eagle is vice president of Strategic Alliances and Partnerships for the Global Oncology business unit at Pfizer where he is involved in nurturing business to business interactions and partnerships. As part of that role, he has been lead the integration of the Pfizer/Wyeth oncology businesses combining the oncology portfolios, he has been involved in several oncology deals including out-license of oncology compounds and partnership deals. Dr. Eagle has led the diagnostic business strategy for oncology business unit. Concurrently. Dr. Eagle is a director of Assured Pharmacy Inc. (OTCBB:APHY), a US based pain specialty pharmacy, Director of Regenicin (OTCBB:RGIN) and advises several small biotech business on business strategy and financial raises. Previously Dr. Eagle headed up the global and US oncology medical and outcomes research group for Pfizer Inc. In this position he oversaw the medical and outcomes programs of Pfizer’s oncology business including clinical trials from phase I-IV. Dr. Eagle is a member of the Pfizer oncology business unit Executive leadership and portfolio strategy team, and a member of the portfolio risk assessment committee for Pfizer. Dr. Eagle has lead or been directly involved with teams that resulted in 9 new products or indications and 4 co-promotes and research collaborations with several co-operative and government organizations including NCI.
Dr. Eagle has previously served on the American Society of Cancer Prevention committee. Dr. Eagle is experienced in global pharmaceutical business and is board certified equivalent in hematooncology and laboratory hematology receiving his training in Australia. Dr. Eagle has extensive clinical and research experience, drug development and commercialization experience of new pharmaceuticals including new product launches.
Profile: Dr. Craig Eagle was appointed to our board of directors on September 7, 2010. He currently serves as Vice President of Strategic Alliances and Partnerships for the Oncology business unit at Pfizer Inc. Dr. Eagle joined Pfizer Australia in 2001 as part of the medical group and has held various positions and over the years including his appointment in 2003 as the worldwide leader for development of Celecoxib in oncology to oversee the global research program. In 2007, he became head of the oncology therapeutic area medical group for Pfizer, including the United States oncology business.
Dr. Eagle attended medical school at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney. He was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA). After his training he performed basic research at the Royal Prince of Wales Hospital to develop a new monoclonal antibody to inhibit platelets. He joined Pfizer Australia in 2001 as part of the medical group. In Australia, his role involved leading and participating in scientific research, regulatory and pricing & re-imbursement negotiations for compounds in therapeutic areas including oncology, anti-infectives, respiratory, arthritis and pain management.
In 2003, Pfizer relocated Dr. Eagle to the United States where he was appointed as the worldwide lead for development of Celecoxib in oncology to oversee the global research program. Since that time he has had increasing responsibility for overseeing the global research plans and teams for Irinotecan and Dalteparin. In 2007, he became head of the oncology therapeutic area global medical group for Pfizer, including the US oncology business. Dr. Eagle has led, or been directly involved with, teams that resulted in eight new products or indications. As part of his current role at Pfizer, he has led the integration of the Pfizer/Wyeth oncology businesses and portfolio